Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 19M | 19M | 21M | 16M | 11M |
| Gross Profit | 3M | 6M | 8M | 5M | 3M |
| Operating Income | -6M | -3M | -639K | -1M | -906K |
| EBITDA | -5M | -3M | 287K | -527K | 50K |
| Net Income | -6M | -3M | -145K | -928K | -103K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$5.72
-1.21% today
1Y Change
+23.28%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Precision Optics Corporation, Inc. (POCI) is a Healthcare stock with a market cap of $30.00M and listed on NASDAQ. The stock last traded around $5.72 and up 23.3% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of -0.1%, EPS growth of -73.5%, a dividend yield of 0.0%. What stands out right now is revenue -0.1%, EPS -73.5%, free cash flow -26.8% with operating margin -27.6% and ROIC -49.0%. Valuation is more restrained than many high-expectation growth names at price/sales 1.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines POCI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
POCI
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
POCI Max Drawdown
-34.34%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for POCI and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$10.7M
-31.9% YoY
FY Net Income
-$102.8K
+88.9% YoY
Free Cash Flow
-$75.8K
+93.0% YoY
Revenue Growth
-0.1%
EPS Growth
-73.5%
Gross Margin
9.7%
Net Margin
-28.3%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 19M | 19M | 21M | 16M | 11M |
| Gross Profit | 3M | 6M | 8M | 5M | 3M |
| Operating Income | -6M | -3M | -639K | -1M | -906K |
| EBITDA | -5M | -3M | 287K | -527K | 50K |
| Net Income | -6M | -3M | -145K | -928K | -103K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2M | 405K | 3M | 606K | 862K |
| Total Assets | 20M | 17M | 20M | 17M | 6M |
| Total Liabilities | 8M | 7M | 8M | 8M | 3M |
| Shareholder Equity | 12M | 10M | 12M | 9M | 3M |
| Total Debt | 2M | 3M | 3M | 3M | 252K |
| Net Debt | 263K | 3M | 234K | 2M | -610K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
47K
+105.0% YoY
Capital Expenditures
122K
+19.9% YoY
Free Cash Flow
76K
+93.0% YoY
Key ratios
Gross Margin
9.7%
Operating Margin
-27.6%
Net Margin
-28.3%
ROE
-60.6%
Debt / Equity
0.47x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.